Virtue Capital Management’s GSK GSK Stock Holding History

Virtue Capital Management’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-582	Closed	-$29K	–	299
2018 Q1	$29K	Buy	+582	New	+$27.1K	0.02%	280

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Virtue Capital Management's GSK Position: Q2 2018 in Review

Virtue Capital Management sold out of GSK (GSK) in Q2 2018, closing a stake of 582 shares — an estimated $29K sold.

Virtue Capital Management first reported a position in GSK in Q1 2018 and held it in 1 quarter. The position peaked at $29K in Q1 2018. 787 funds tracked by Wall St. Rank hold GSK as of Q2 2018.

Virtue Capital Management reported no remaining GSK position as of Q2 2018 after selling out during the quarter.
Virtue Capital Management sold 582 GSK shares in Q2 2018, an estimated $29K.
Virtue Capital Management first reported a position in GSK in Q1 2018 and held it in 1 quarter.
Virtue Capital Management's GSK position peaked at $29K in Q1 2018.
787 funds tracked by Wall St. Rank held GSK as of Q2 2018.

Based on Virtue Capital Management's 13F filing for Q2 2018, filed 14 Aug 2018.